Melanotan I is the developmental name for afamelanotide, a synthetic analog of alpha-melanocyte-stimulating hormone approved as the prescription implant Scenesse for a single rare disease. The honest bottom line is that only this regulated form, delivered by a clinician for erythropoietic protoporphyria, carries marketing approval; the injectable tanning products that share the "Melanotan" name are unlicensed and unproven. That distinction between the two is the central fact of the compound.
Melanotan I, marketed as afamelanotide (Scenesse), is approved solely for erythropoietic protoporphyria in adults, receiving EMA approval in 2014 and FDA approval in 2019.
Afamelanotide is a first-generation synthetic melanocortin peptide, structurally [Nle4, D-Phe7]-alpha-MSH, whose approved product is sold as Scenesse by Clinuvel. Two amino-acid substitutions, norleucine at position four and D-phenylalanine at position seven, make the 13-residue molecule far more resistant to the enzymes that degrade the natural hormone within minutes. Regulators classify the finished product as a photoprotective agent, not a cosmetic.
Afamelanotide is a 13-amino-acid melanocortin-1 receptor agonist ([Nle4, D-Phe7]-alpha-MSH) classified by regulators as a photoprotective agent rather than a cosmetic.
Afamelanotide produces its effect by mimicking the body's own alpha-MSH and binding the melanocortin-1 receptor on melanocytes. The measured result is a shift toward eumelanin, the brown-black pigment that absorbs ultraviolet and visible light and helps neutralize the reactive oxygen species that light generates in skin.
By binding the melanocortin-1 receptor and raising cyclic AMP, afamelanotide drives eumelanin production, the darker pigment that raises the skin's tolerance to ultraviolet and visible light.
The single approved indication for afamelanotide is erythropoietic protoporphyria in adults, a rare inherited disorder in which protoporphyrin IX accumulates in skin and reacts with sunlight to cause burning pain within minutes. The approval is narrowly worded, and regulators explicitly separate it from cosmetic tanning.
Afamelanotide holds marketing approval for one indication only, erythropoietic protoporphyria in adults, and regulators explicitly exclude cosmetic tanning from that approval.
The central documented benefit of afamelanotide is a longer stretch of time in sunlight before a painful reaction begins, a meaningful gain for a population whose disease severely restricts outdoor life. It darkens the skin in a way that resembles a tan but is produced without ultraviolet exposure and without the DNA damage that accompanies sunbed or sun-driven tanning.
In the clinical trials supporting approval, afamelanotide increased pain-free light exposure and improved patient-reported quality of life in adults with erythropoietic protoporphyria.
In its approved medical form, afamelanotide's reported side effects are generally mild, but the risk picture splits sharply by the source of the product. The unregulated "Melanotan" sold online carries a materially different and more concerning profile.
In its approved form afamelanotide's side effects are generally mild, such as nausea and implant-site reactions, whereas unregulated "Melanotan" products of unknown purity and dose have drawn repeated regulator warnings.
As an approved medicine, afamelanotide is prescription-only and can be supplied lawfully only through authorized specialist channels for its licensed indication. That status stands in sharp contrast to the unlicensed "Melanotan" peptides sold for cosmetic tanning, which hold no marketing authorization and are illegal to sell as medicines in many jurisdictions.
Afamelanotide is a prescription-only medicine, while the unlicensed "Melanotan" peptides marketed for tanning hold no marketing authorization and have drawn public warnings from the US FDA and the UK's MHRA.
In its approved form, afamelanotide is not self-injected but a controlled-release solid implant placed under the skin by a trained physician. This tightly controlled administration is a defining difference from the unregulated market, where powders are reconstituted and self-injected with no standardized dose or sterility assurance.
In its approved form afamelanotide is delivered as a fixed-dose subcutaneous implant placed by a trained clinician, commonly repeated about every two months during the sunlight season, rather than as a self-injected drug.
Melanotan I and Melanotan II share a name and an origin in melanocortin research, but they are distinct molecules with different pharmacology. The colloquial "Melanotan" label obscures that only one has been developed, tested, and approved as a controlled medicine.
| Criteria | Melanotan I (afamelanotide) | Melanotan II |
|---|---|---|
| Structure | Linear alpha-MSH analog | Smaller cyclic peptide |
| Receptor activity | Relatively selective for MC1R | Broad, including MC4R (libido, appetite) |
| Regulatory status | Approved prescription medicine | No marketing approval anywhere |
| Side-effect profile | Narrower, pigment-focused | Wider and less predictable |
Melanotan I (afamelanotide) is a relatively MC1R-selective, approved prescription medicine, whereas Melanotan II is a broader melanocortin agonist with no marketing approval anywhere and a wider side-effect profile.
As an orphan drug for a rare disease, afamelanotide carries a high price that reflects a small patient population and the specialist delivery it requires. Access runs through manufacturer-accredited specialist centers rather than ordinary pharmacies, so availability is geographically uneven.
Afamelanotide is priced as an orphan drug and distributed only through manufacturer-accredited specialist centers, with reimbursement for eligible erythropoietic protoporphyria patients varying by jurisdiction.
Educational use only. This article describes what the published scientific and clinical literature reports about Melanotan I. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
